Tempus publishes investor deck on planned Personalis acquisition to expand MRD testing platform

• Tempus outlined plans to buy Personalis for USD 16.25 per share, valuing the deal at USD 1.7 billion, or USD 1.5 billion net.
• Consideration set as TEM stock with up to 50% cash at Tempus’ option; floating exchange ratio capped at 0.3356 TEM shares.
• Transaction expected to close no earlier than Q4 2026, subject to Personalis shareholder vote and regulatory clearance.
• Deal targets tighter integration of Personalis’ MRD testing into Tempus’ precision oncology platform, expanding exposure to a USD 20+ billion U.S. MRD market.
• Personalis cited more than 35,000 total tests, 10,384 Q2 volume, 33% sequential growth, and assay sensitivity down to 1.67 parts per million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.